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Drug resistance is one of the principal obstacles blocking worldwide malaria control. In Colombia, malaria 
remains a major public health concern and drug-resistant parasites have been reported. In vitro drug susceptibility 
assays are a useful tool for monitoring the emergence and spread of drug-resistant Plasmodium falciparum. The 
present study was conducted as a proof of concept for an antimalarial drug resistance surveillance network based 
on in vitro susceptibility testing in Colombia. Sentinel laboratories were set up in three malaria endemic areas. The 
enzyme linked immunosorbent assay-histidine rich protein 2 and schizont maturation methods were used to assess 
the susceptibility of fresh P. falciparum isolates to six antimalarial drugs. This study demonstrates that an antima-
larial drug resistance surveillance network based on in vitro methods is feasible in the field with the participation of 
a research institute, local health institutions and universities. It could also serve as a model for a regional surveil-
lance network. Preliminary susceptibility results showed widespread chloroquine resistance, which was consistent 
with previous reports for the Pacific region. However, high susceptibility to dihydroartemisinin and lumefantrine 
compounds, currently used for treatment in the country, was also reported. The implementation process identified 
critical points and opportunities for the improvement of network sustainability strategies. 
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Malaria is an important public health problem world-
wide; it causes an estimated 225 million clinical cases and 
781,000 deaths per year, predominately in Sub-Saharan 
Africa (WHO 2010). In Colombia, approximately 79,000 
malaria cases are reported annually, with Plasmodium 
vivax accounting for the most infections (approximately 
72%) followed by Plasmodium falciparum (27%) (INS 
2010). Eighty percent of Colombian territory is at risk 
for malaria transmission; moreover, the Pacific region 
shows the highest incidence for P. falciparum infections 
with 9.3 cases per every 1,000 inhabitants in 2006. In 
fact, approximately 40% of all P. falciparum cases re-
ported in Colombia annually occur in this region. Other 
endemic areas are the Urabá bajo-Cauca, Alto-Sinú and 
the Orinoco-Amazon basin (INS 2010).
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Since P. falciparum resistance to chloroquine (CQ) 
was reported in the early 1960s and its subsequent world-
wide dissemination, several strategies to monitor anti-
malarial drug resistance have been proposed. Surveil-
lance is important for the early detection of antimalarial 
drugs with decreased efficacy and the consequent updat-
ing of drug policies (Noedl et al. 2003). Clinical studies 
have been considered the gold standard for drug resis-
tance surveillance because they take into account host, 
parasite and drug interactions (OPS-OMS 1998, WHO 
2003). However, these studies are costly and logistically 
complex in countries such as Colombia that have a low-
moderate intensity of transmission with limited access 
to malaria endemic areas (Ruebush et al. 2003). Clini-
cal efficacy studies of antimalarial drugs in Colombia 
have shown therapeutic failures of up to 90% in patients 
with uncomplicated P. falciparum malaria treated with 
CQ. This evidence was the basis for changing the na-
tional antimalarial drug policy in 1999, when CQ was 
replaced by amodiaquine (AQ) combined with sulfadox-
ine/pyrimethamine (SP) as the treatment of choice (MS 
1999, Osorio et al. 1999, 2002, blair et al. 2001, 2006, 
blair-Trujillo et al. 2002, Castillo et al. 2002). Similarly, 
therapeutic failures to AQ have reached up to 50% in the 
Pacific coast region and therapeutic failures to SP have 
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reached up to 87% in the Amazon Region (Osorio et al. 
2007). Since 2006, artemisinin-based combination ther-
apy (ACT) [artemether/lumefantrine (LUM)] has been 
implemented in Colombia. 
The limitations of clinical studies for monitoring an-
timalarial drug efficacy highlight the need for alterna-
tive surveillance methods. Although in vitro methods do 
not replace in vivo methods, they allow for the detection 
of intrinsic variations in parasites and help identify when 
and where to conduct efficacy surveys. Enzyme linked 
immunosorbent assay (ELISA)-based in vitro drug sus-
ceptibility assays have shown accurate results in the 
field. In particular, the ELISA for histidine rich protein 
2 (HRP2) has been described as a reliable method for 
assessing P. falciparum susceptibility to antimalarial 
drugs in both cultured and fresh isolates. It has shown 
a high correlation with the microscopy schizont matura-
tion test and radioisotopic tests (Noedl et al. 2002, 2004). 
The present study was conducted as a proof of feasibility 
of a surveillance network to monitor antimalarial drug 
resistance using in vitro susceptibility tests performed 
directly in endemic areas of Colombia.
PATIENTS, MATERIALS AND METHODS
Study area - Three sentinel sites were selected taking 
into account the incidence of P. falciparum malaria, pre-
vious reports of therapeutic failures and their strategic 
location (border area). Two sentinel sites were set up in 
the Pacific region: Tumaco (state of Nariño) in the South 
(1º49’N 78º52’W) and Quibdó (state of Chocó) in the 
North (5º43’N 76º37’W). The third site, Leticia (state of 
Amazonas) (4º10’S 69º57’W), was located in the Ama-
zon Region. Although this state has a relatively low in-
cidence of P. falciparum malaria (1.2/1,000 inhabitants 
in 2009 compared to 6.5 in Chocó and 9.1 in Nariño), 
they report more therapeutic failures to SP than Pacific 
region states (Osorio et al. 2007, INS 2010). Leticia is 
located on the borders with brazil and Peru, where high 
levels of therapeutic failures have been reported for both 
CQ and SP (Ruebush et al. 2003).
Study population - Patients visiting the Ismael Roldan 
Valencia Hospital or the San Vicente health facility in 
Quibdó, the Instituto Departamental de Salud de Na-
riño/Laboratorio de Control de Vectores in Tumaco and 
the Laboratorio de la Secretaría Departamental de Salud 
de Amazonas/Programa de Enfermedades Transmitidas 
por Vectores in Leticia were eligible for the study if they 
met the inclusion criteria: (i) ≥ seven years of age, (ii) P. 
falciparum monoinfection, (iii) parasitaemias between 
500-100,000 trophozoites/µL and (iv) absence of CQ in 
the urine (negative Saker-Solomons test) (Saker & Solo-
mons 1979) (Figure). Patients with clinical evidence of 
severe malaria were excluded.
Laboratory procedures - In 2006, the in vitro assays 
were performed by study site technicians; the techni-
cians had previously been trained at the Centro Inter-
nacional de Entrenamiento en Investigaciones Médicas 
(CIDEIM). In 2007, two undergraduate clinical microbi-
ology students were engaged in the project and trained at 
CIDEIM as part of their internships due to time restric-
tions regarding the availability of personnel in Tumaco 
and Quibdó. Venous blood samples (4 mL) were taken 
in ethylenediamine tetraacetic acid vacutainers (becton 
Dickinson) from eligible subjects and processed fresh. 
Parasitaemia and monoinfection with P. falciparum was 
confirmed through thick and thin blood smears. Sam-
ples with parasitaemias ≥ 15,000 trophozoites/µL were 
adjusted to 5,000 trophozoites/µL using uninfected O+ 
erythrocytes for a final concentration of 0.1% of parasit-
ized red blood cells. Parasite solutions were prepared with 
1.5% haematocrit in Roswell Park Memorial Institute 
(RPMI) 1640 medium (Sigma-Aldrich) supplemented 
with 0.5% albuMAX I® (GIbCO), 25 mM HEPES (Sig-
ma-Aldrich), 25 mM NaHCO3 (pH 7.3) (Sigma-Aldrich), 
10 units/mL of penicillin and 10 µg/mL of streptomycin 
(Sigma-Aldrich); next, 200 µL of the parasite solutions 
were added to each well. Positive controls (4-6 per plate) 
of parasite solutions without drug and negative controls 
(2 per plate) of uninfected blood without drug were in-
cluded. Samples were incubated at 37ºC in a standard 
atmosphere of 5% CO2, 5% O2 and 90% N2 in Quibdó. 
Samples were incubated under a candle jar atmosphere in 
Tumaco and Leticia due to the infeasibility of transport-
ing the special gas mixture to these towns. Two identical 
plates were prepared for each sample. Parasite suscepti-
bility was assessed through the ELISA-HRP2 method in 
one plate (Noedl et al. 2002) and by a modified schizont 
maturation method (Noedl et al. 2004) in the other plate. 
The microscopy schizont method was stopped when the 
parasites reached at least 10% schizont maturation in the 
positive control well. To find the precise moment to stop 
the experiment, the developing parasites in the positive 
control wells were examined microscopically beginning 
at the 16th hour of incubation. If there were not enough 
schizonts at this time (< 10%), the plate was incubated 
again and checked periodically up to the 48th h of incu-
bation. The time between checks was judged based on 
the maturation rate. All wells were harvested as Giem-
sa-stained thick smears according to the World Health 
Organization protocol guideline (WHO 2001). The per-
centage of schizonts was determined as the number of 
schizonts (with 3 or more nuclei) in 200 asexual forms 
using light microscopy (1,000X).
 For the ELISA-HRP2 assays, the incubation period 
was 72 h; assays were performed using a commercially 
available kit (Cellabs) following the manufacturer’s in-
structions. briefly, plates were frozen and thawed twice 
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to release the antigen through parasite lysis. To determine 
whether the parasites had adapted to culture and the op-
timal sample dilution prepared antigen dilutions for each 
sample, we assessed several dilutions (1:2.5, 1:3.3, 1:5 and 
1:10) from the positive control and the highest mefloquine 
(MQ) concentration well, where no parasite growth was 
expected. The assays were considered valid if the optical 
density ratio between the positive and basal controls (in-
dex growth) was ≥ 1.7 (Kaddouri et al. 2006). 
Antimalarial drug assay - To assay antimalarial drug 
efficacy, 96-well plates (becton Dickinson) were pre-
coated at CIDEIM with six antimalarials: CQ diphos-
phate (Sigma-Aldrich), AQ (Sigma-Aldrich, provided 
by Walter Reed Army Medical Centre), desethylamo-
diaquine (MAQ) (Sigma-Aldrich, provided by WHO), 
MQ hydrochloride (Sigma-Aldrich), dihydroartemisinin 
(DHA) (Sigma-Aldrich) and LUM (Novartis). Stock so-
lutions of CQ, AQ and MAQ were diluted in distilled wa-
ter; MQ and DHA were diluted in methanol. LUM was 
diluted in acid methanol (methanol: acetic acid 99.8 mL 
+ 0.2 mL) (Annerberg et al. 2005). Seven serial dilutions 
(in RPMI 1640, 1:2) for each drug were pipetted into the 
wells and the plates were left to dry under sterile condi-
tions. To cover a wide range of parasite drug sensitivi-
ties, the drug concentrations ranges were 50-3,200 nano-
moles/liter (nM) for CQ, 5-320 nM for AQ and MAQ, 
2.5-160 nM for MQ, 0.5-32 nM for LUM and 0.3-16 nM 
for DHA. Drug plate quality control was performed at 
CIDEIM using the reference strain W2 (Indochina) and 
CQ resistance and MQ susceptible strains (provided by 
Dr Mariano Zalis, Institute of biophysics Carlos Chagas 
Filho, Rio de Janeiro University, brazil). Afterwards, 
the drug plates were transported refrigerated (4-8ºC) to 
the sentinel sites and used within two months of prepara-
tion (Houzé et al. 2007). LUM was tested only in 2007 
and AQ was not tested in Leticia.
Data analysis - The drug concentrations that inhibit-
ed 50% of parasite growth compared to control samples 
without drug (IC50) were calculated using a non-linear 
regression model with the software Hn-NonLin, which 
is available from malaria.farch.net. A database was cre-
ated in Epi Info 6.04d (CDC) and analysed with Stata 
9.2 for Windows (StataCorp LP 2006). The IC50 were 
log-transformed and geometric means were obtained. 
IC50 among drugs at each sentinel site and between years 
were compared using a t-test. The WHO schizont matu-
ration method and the ELISA-HRP2 were compared us-
ing the Spearman correlation coefficient. A p value of < 
0.05 was considered statistically significant. 
Quality control - Each year, all microtest slides from 
three randomly selected samples at each sentinel site 
were checked at the CIDEIM by an expert microscopist 
and new IC50 were obtained. The first and second IC50 
readings of each drug and sample were compared us-
ing the intraclass correlation coefficient. The correlation 
coefficient in Quibdó was 0.87 (95% CI, 0.64-0.96) in 
2006 and 0.95 (95% CI, 0.88-0.99) in 2007. In Tumaco, 
the correlation coefficient was 0.99 (95% CI, 0.96-0.99) 
in 2006 and 0.96 (95% CI, 0.89-0.98) in 2007. In Leticia, 
the correlation coefficient was 0.64 (95% CI, -0.04-0.92) 
in 2006. Therefore, in Leticia, personnel were retrained 
and all slides from 2006 and 2007 were read again at the 
CIDEIM; the results read at the CIDEIM were used for 
analysis. The quality control of ELISA-HRP2 was per-
formed on site during initiation, middle and end moni-
toring visits. Three samples were re-evaluated in the 
field and the coefficients of variation between the IC50 
values were obtained.
Ethics - Informed, written consent was obtained from 
subjects aged 18 years or older. For those aged less than 
18 years, written consent from a parent or guardian was 
obtained in addition to patient assent. All subjects re-
ceived their regular antimalarial treatment regardless of 
their decision to participate. The study was approved by 
the Ethical Review board of the CIDEIM and performed 
within the framework of ethical policies of Colombia and 
the Helsinki Declaration and its amendments. 
RESULTS
A total of 121 P. falciparum samples were included 
in the study; of these, 51 were collected during 2006, 
while 70 were collected in 2007. Of the total 121 sam-
ples, 104 (47 and 57, respectively) were processed (Fig-
ure). The geometric mean parasitaemia of samples was 
9,020 trophozoites/µL (range, 1,004-45,000 trophozo-
ites/µL). Overall, successful experiments were obtained 
for 85.5% (89/104) of samples. Sixty-four percent (57/89) 
with both methodologies (schizont maturation method 
and ELISA-HRP2) and 36% (32/89) using just one of 
those. Some schizont maturation test results were not 
accurate due to a new parasite cycle that started in less 
than 18 h of culture, which invalidates the assay (3 as-
says). This situation was observed mainly in Quibdó, 
where some samples grew as fast as 16 h. In contrast, 
all samples in Leticia had incubation times of 29 h or 
more. Similarly, the mean growth index observed in the 
ELISA-HRP2 assays in Quibdó (6.6; range, 1.5-20) was 
nearly double that observed in Tumaco (3.6; range, 1.2-
6.6) and Leticia (3.8; range, 3.6-4.2). 
In vitro antimalarial drug susceptibilities of fresh P. 
falciparum isolates - We classified parasites as exhib-
iting low susceptibility (LS) based their IC50 for each 
drug; parasites with LS had IC50 values of ≥ 100 nM 
for CQ, ≥ 30 nM for AQ, ≥ 60 nM for MAQ, ≥ 30 nM 
for MQ and ≥ 10 nM for DHA and LUM. Otherwise, 
parasites were defined as highly susceptible (HS). Def-
initions for the HS and LS of parasites were based on 
the IC50 of the W2 reference strain, which are shown in 
Table I (Ringwald & basco 1999).
LS to CQ (96.3%, 78/81) and MAQ (83.7%, 67/80) 
was observed at all three sentinel sites for both years. 
In contrast, most samples were HS to AQ (> 85%). All 
samples were HS to DHA (IC50 < 10 nM) and LUM (IC50 
< 10 nM). Although most samples were HS to MQ, three 
from Quibdó exhibited LS to MQ. The IC50 obtained 
during the two years of the study are listed in Table II.
because different incubation methods were used in 
Quibdó compared to Tumaco and Leticia, we cannot 
compare the results between sites. However, the results 
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from Tumaco and Leticia, which were obtained under 
the same conditions, showed HS to CQ and MQ in Leti-
cia compared to Tumaco; this difference was stable and 
statistically significant both in years (p < 0.001) (Table 
II). The Spearman correlation between the two in vitro 
susceptibility methods (HRP2 and schizont maturation) 
was p = 0.938 (p < 0.001).
DISCUSSION
As a drug resistance surveillance tool, one of the 
advantages of in vitro methodologies is the ability to 
measure P. falciparum susceptibility to several antima-
larial drugs simultaneously in the field. This allows for 
the early detection of changes in the intrinsic parasite 
response to antimalarial drugs, helping to prioritise, in 
terms of timing and location, efforts to further evaluate 
drug efficacy through in vivo surveys.
The sustainability of a surveillance system should be 
considered prior to implementation. In our case, we iden-
tified the need to involve local health authorities as well 
as local technical staff. In addition, we suggest that short 
training periods of 30 days and minimal supervision of 
clinical microbiology undergraduate students (interns at 
CIDEIM) can strengthen in vitro technical ability at field 
locations. Human resources are critical for the continuity 
of the surveillance system. The research centre (in this 
case CIDEIM) provided technology and scientific transfer 
to personnel (technicians) from endemic areas and contin-
ues to coordinate the logistics and laboratory activities.
This study is limited in its ability to establish geo-
graphical variations in drug susceptibility because of 
differences in the incubation conditions between sites. 
Parasites were incubated using a gas mixture in Quibdó 
and candle jar in Tumaco and Leticia. The parasite index 
growth was 2.5 times higher in Quibdó compared to Tu-
maco and Leticia, which could be explained by differences 
in culture conditions. In particular, the candle jar method 
provides an approximate balance of 1.1-3.3% of CO2 and 
14.5-17.8% of O2 in contrast to the prepared gas mixture 
of 5% CO2 and 5% O2 (Trager & Jensen 1976, Scheibel 
et al. 1979). Previous studies have shown that variations 
in O2 concentrations can affect parasite growth (briolant 
et al. 2007) and that CO2 concentration can affect the 
IC50 of pH-dependant antimalarials such as CQ (basco 
2007). These facts highlight the importance of keeping 
standardised procedures for culture conditions and for the 
quality control of pre-dosed drug plates. For instance, in 
situations where the gas mixture is unavailable at field 
sites, an alternative method would be to evaluate reference 
strains at a central lab using field conditions, which would 
enable the results to be normalised. The World Wide An-
timalarial Resistance Network aims to contribute towards 
these objectives (bacon et al. 2007).
Additionally, the inoculum effect is an important 
concern in the standardisation of in vitro assays. This ef-
fect leads to an apparent decrease in drug activity in sit-
uations of high parasitaemia, causing a false resistance/
tolerance result (Gluzman et al. 1987). In these experi-
ments, it was demonstrated that parasitaemias of up to 
0.5% were reasonable for in vitro assays without the in-
terference of the inoculum effect. Consistent with these 
results, Dr basco stated that: “At parasitaemia, > 1%, 
the inoculum effect is observed. The starting parasitae-
mia must be adjusted to 0.1-1% for optimal measurement 
of parasite growth and drug response” (basco 2007). In 
our work, the maximum evaluated parasitaemia was up 
to 14,000 trophozoites/μL, which corresponds to 0.28% 
and falls in the range suggested above.
Several events could have affected the in vitro test 
results. We did not obtain results in 34 ELISA-HRP2 
assays because of the following situations: (i) failure to 
maintain temperature conditions due to power outage (8, 
all from Tumaco), (ii) HRP2-antigen was not detected 
with the commercial kit (13 samples, all from Leticia) 
and (iii) the ratio between positive and basal controls 
was less than 1.7 (5 samples from Leticia, 6 from Tu-
maco and 2 from Quibdó).
We suggest that for the implementation of the ELISA-
HRP2 assay at field sites, the following procedures and 
guidelines should be adopted. Prior to sample processing 
with the HRP2 kit, we performed a pretest curve that al-
lowed us to determine the optimal antigen dilution, while 
also providing evidence as to whether the parasite had 
been adapted to culture without using an entire plate. We 
observed that optical densities varied widely between 
isolates; consequently, the same antigen dilution factors 
could not necessarily be applied to different samples. This 
variability in HRP2 detection could be a result of differ-
TAbLE I
IC50 reference strain W2-Plasmodium falciparum
IC50 nM (95% CI)
CQ AQ MAQ MQ DHA LUM
LS (≥ 100)
625.3
(545.9-704.6)
LS (≥ 30)
20.1
(11.5-28.6)
LS (≥ 60)
195.5
(164.8-226.2)
HS (< 30)
7.3
(5.0-9.7)
HS (< 10)
2.3
(1.2-3.4)
HS (< 10)
2.5
(2.5-2.5)
AQ: amodiaquine; CI: confidence interval; CQ: chloroquine; DHA: dihydroartemisinin; HS: high susceptibility; IC: inhibitory 
concentration; LS: low susceptibility; LUM: lumefantrine; MAQ: desethylamodiaquine; MQ: mefloquine; nM: nanomoles/liter. 
Results obtained from two experiments. 
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ences in initial parasitaemia, time of patient infection, ge-
netic variability or the differential expression pattern of 
the HRP2 protein, factors that all influence the antigen-
antibody reaction (baker et al. 2005, Lee et al. 2006). Ad-
ditionally, 65% (13/20) of the samples from Leticia that 
were successfully analysed with the schizont matura-
tion method did not yield results using the ELISA-HRP2 
methodology due to undetectable levels of HRP2. These 
results suggest the presence of genetic polymorphisms in 
HRP2 or that a proportion of P. falciparum isolates from 
this region do not produce HRP2 or HRP3 (Uguen et al. 
1995, Traore et al. 1997, Gamboa et al. 2010). 
The recruitment and compliance of patients was par-
ticularly high in Tumaco and Quibdó in 2007, when per-
sonnel were dedicated full-time to the in vitro assays. 
The experience gained in the field with the ELISA-based 
TAbLE II
Plasmodium falciparum geometric mean IC50 (nM) obtained each year per sentinel site  
according to the in vitro susceptibility assay used
A. Quibdó
Year Test
IC50 (nM) of antimalarial drug (95% CI)
CQ (n) AQ (n) MAQ (n) MQ (n) DHA (n) LUM (n)
2006 1 426.7 (15)
(291.5-624.6)
23.3 (15)
(17.6-30.8)
130.1 (15)
(98-172.6)
38.5 (15)
(26-57.2)
0.5 (14)
(0.4-0.8)
ND
-
2 412.3 (15)
(314.2-541.1)
23 (15)
(17.8-29.6)
106.6 (14)
(85.3-133.4)
36.2 (15)
(27.39-47.93)
0.8 (15)
(0.6-1.1)
ND
-
2007 1 248.4 (18)
(188.9-326.8)
14.3 (18)
(11.9-17.3)
68.3 (18)
(53.6-87.2)
44.1 (18)
(32.6-59.8)
1 (14)
(0.82-1.39)
4.1 (4)
(1.3-12.6)
2 177.4 (17)
(133.8-235.2)
12.8 (17)
(10.4-15.7)
47 (17)
(36.2-61)
29.4 (17)
(23-37.7)
1.2 (13)
(0.9-1.8)
2.6 (4)
(2.3-3)
b. Tumaco
Year Test
IC50 (nM) of antimalarial drug (95% CI)
CQ (n) AQ (n) MAQ (n) MQ (n) DHA (n) LUM (n)
2006 1 319.2 (9)
(278.7-365.6)
25.1 (9)
(19-33.2)
134.7 (9)
(105.2-172.6)
17 (8)
(9.4-30.7)
0.9 (1)
-
ND
-
2 140.7 (1) 17.6 (1) 173.4 (1) 7.4 (1) ND ND
2007 1 341.5 (21)
(272.5-428)
23.1 (21)
(18.6-28.6)
120.6 (20)
(94.4-154.1)
24.2 (21)
(17.3-33.9)
0.8 (21)
(0.6-0.9)
4.5 (5)
(2.4-8.5)
2 213.5 (17)
(174.4-261.3)
21.3 (17)
(17.3-26.3)
109.2 (16)
(86.2-138.3)
22.7 (17)
(17.7-29.2)
1 (17)
(0.8-1.1)
4 (5)
(1.7-9)
C. Leticia
Year Test
IC50 (nM) of antimalarial drug (95% CI)
CQ (n) AQ (n) MAQ (n) MQ (n) DHA (n) LUM (n)
2006 1 140.7 (1) 17.6 (1) 173.4 (1) 7.4 (1) ND ND
2 160.5 (12)
(123-209.6)
ND
-
102.8 (12)
(80.3-131.6)
9.1 (11)
(7-12.2)
ND
-
ND
-
2007 1 162.2 (6)
(133.7-196.8)
20.3 (2)
(12.5-33.1)
119.2 (6)
(85.4-166.2)
7.1 (6)
(3.8-13.3)
1.9 (2)
(1.7-2.2)
< 2.5 (1)
-
2 109.2 (3)
(42.5-280.4)
17.2 (2)
(6.3-46.6)
91 (3)
(24.4-339.4)
7.7 (3)
(1.7-33.1)
0.6 (2)
(0.4-0.8)
< 2.5 (2)
-
AQ: amodiaquine; CI: confidence interval; CQ: chloroquine; DHA: dihydroartemisinin; IC: inhibitory concentration; LUM: 
lumefantrine; MAQ: desethylamodiaquine; MQ: mefloquine; n: number of samples tested; ND: not determined; test 1: micro-
scopic evaluation; test 2: enzyme linked immunosorbent assay-histidine rich protein 2.
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methods will allow for a replacement of subjective and 
laborious methods such as the schizont maturation as-
say. Although the ELISA-HRP2 method could be used 
routinely at field sites in endemic areas, implementa-
tion still requires site-specific adjustments that had not 
been previously described when assessing fresh P. fal-
ciparum parasites.
A high prevalence (96.3%) of parasites with in vitro 
LS to CQ (IC50 > 100 nM) was found at all sentinel sites. 
These results concur with the low efficacy of CQ against 
P. falciparum throughout Colombia that has been previ-
ously reported in therapeutic efficacy studies (Osorio et 
al. 1999, 2002, blair et al. 2001, 2006, blair-Trujillo et 
al. 2002, Castillo et al. 2002). Despite the fact that CQ 
was withdrawn for P. falciparum treatment in Colombia 
as early as 2000, it is still in use for P. vivax infections 
and remains available in the market, possibly enabling it 
to exert drug selection pressure on P. falciparum strains. 
Also, more than 80% of parasites exhibited a markedly 
reduced sensitivity to MAQ (IC50 > 60 nM), which is 
consistent with therapeutic efficacy studies showing that 
AQ is no longer useful for the treatment of P. falciparum 
malaria. This is especially the case for Tumaco, where 
therapeutic failures of up to 50% have been reported 
(González et al. 2003). 
Our results showed high sensitivity of P. falciparum 
to DHA and LUM at all three sentinel sites, predicting 
a high efficacy for the ACT approach recently imple-
mented in Colombia. The relatively LS of parasites to 
MQ found in Quibdó requires close monitoring due to 
the potential emergence and spread of resistance to this 
drug. This finding could be explained by the use of ha-
lofantrine, a phenanthrenemethanol-type amino alcohol 
that has shown cross-resistance with MQ (Cowman et al. 
1994), which is available in Quibdó but not at the other 
two sentinel sites. 
In vitro surveillance networks together with molecu-
lar markers, clinical trials and pharmacokinetics are use-
ful tools in the documentation of emerging drug resis-
tance (bacon et al. 2007, Sibley et al. 2008). This study 
shows that an antimalarial drug resistance surveillance 
network based on in vitro methods is feasible in Colom-
bia and possibly in other Latin America countries where 
therapeutic efficacy studies are costly and limited.
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